Beximco makes historic drug shipment to Kuwait

Generic pharmaceutical manufacturer Beximco announced on Friday that it has commenced the export of pharmaceuticals to Kuwait.

The AIM-traded firm said it marks the first time a Bangladeshi pharmaceutical company has launched products in any Gulf member country under the Gulf Cooperation Council.

A launch ceremony was held at Beximco’s factory in Dhaka to mark the shipment in the presence of the Ambassador of Kuwait, Adel Mohammad A. H. Hayat.

Beximco said initial exports to Kuwait from include two metered-dose inhaler products for asthma and other respiratory conditions, namely Azmasol (salbutamol), Bexitrol-F (salmeterol plus fluticasone) and one blood pressure drug Amdocal (amlodipine).

The company said it expects to launch additional products in Kuwait later this year, and estimates the combined Gulf market to be worth $9bn with the Kuwait market alone worth $1.5bn.

“Beximco Pharma continues to build its presence in emerging and developed markets,” said managing director Nazmul Hassan.

“The company is increasingly focused on regulated markets, such as the US, EU, GCC and Australia, where the demand for generic pharmaceutical products is rising.”

Hassan said the Gulf market is an important one for Beximco, and the launch of its products in Kuwait will open up new opportunities in the region.

“We will continue to expand our product range in the Gulf market, providing patients with safe and affordable treatment options,” Hassan explained.